Exchange Traded Concepts LLC Sells 8,031 Shares of DexCom, Inc. $DXCM

Exchange Traded Concepts LLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 80.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,000 shares of the medical device company’s stock after selling 8,031 shares during the period. Exchange Traded Concepts LLC’s holdings in DexCom were worth $133,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of DXCM. SJS Investment Consulting Inc. raised its stake in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in DexCom during the third quarter worth $29,000. CVA Family Office LLC raised its stake in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. Sound Income Strategies LLC raised its stake in DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after buying an additional 285 shares during the last quarter. Finally, Aventura Private Wealth LLC bought a new position in DexCom during the fourth quarter worth $43,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Sanford C. Bernstein reissued an “outperform” rating and set a $86.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Canaccord Genuity Group set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $86.50.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the transaction, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Down 0.2%

Shares of NASDAQ DXCM opened at $63.11 on Wednesday. The stock has a market capitalization of $24.29 billion, a P/E ratio of 30.05, a P/E/G ratio of 1.21 and a beta of 1.55. The company has a 50-day moving average price of $68.70 and a 200-day moving average price of $66.96. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.45 earnings per share. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.